Literature DB >> 23502076

Seronegative antiphospholipid syndrome.

Rabih Nayfe1, Imad Uthman, Jessica Aoun, Ehab Saad Aldin, Mira Merashli, Munther A Khamashta.   

Abstract

APS is an autoimmune disease that leads to arterial and/or venous thrombosis, recurrent pregnancy loss and persistently positive aPLs. Patients with clinical manifestations highly suggestive of APS but persistently negative conventional aPLs are classified as having seronegative APS. Ongoing research has revealed the existence of non-criteria antibodies proposed to be relevant to APS and that can be potentially included in the disease's classification criteria. We present a literature review on the most promising antibodies of this heterogeneous aPL family, which includes antibodies to a zwitterionic phospholipid, namely phosphatidylethanolamine, phospholipid-binding plasma proteins, phospholipid-protein complexes and anionic phospholipids other than cardiolipin. Although these molecules can increase the diagnostic yield of APS, their clinical relevance is still debatable and needs to be confirmed by interlaboratory efforts toward standardizing diagnostic tools, in addition to experimental data and larger longitudinal studies.

Entities:  

Keywords:  anti-β2 glycoprotein I antibodies; antiphospholipid antibodies; antiphospholipid syndrome; phosphatidylethanolamine; pregnancy morbidity; seronegative antiphospholipid syndrome; thrombosis

Mesh:

Substances:

Year:  2013        PMID: 23502076     DOI: 10.1093/rheumatology/ket126

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  30 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  The Laboratory Diagnosis of the Antiphospholipid Syndrome.

Authors:  Jasmina Ahluwalia; Sreejesh Sreedharanunni
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-22       Impact factor: 0.900

3.  An extraordinary case of recurrent stroke, disseminated thrombosis and endocarditis.

Authors:  Liza Mariam Thomas; Niaz Ahmed Shaikh; Ranjana Pradeep
Journal:  BMJ Case Rep       Date:  2018-06-04

Review 4.  The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

Review 5.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

Review 6.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

7.  Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort.

Authors:  N M Heikal; T D Jaskowski; E Malmberg; G Lakos; D W Branch; A E Tebo
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

Review 8.  Renal involvement in primary antiphospholipid syndrome.

Authors:  Carmelita Marcantoni; Carmela Emmanuele; Francesco Scolari
Journal:  J Nephrol       Date:  2016-05-19       Impact factor: 3.902

9.  The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Ljudmila Stojanović; Svetlana Ignjatović; Violeta Dopsaj
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

10.  Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA.

Authors:  Ke Ke; Zachariah I Strango; Paul E Harper; Ming Zhao
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.